Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

European shares log weekly gains, UK's blue-chip index hits record high

Fri, 03rd Feb 2023 17:27

STOXX 600 up 0.3%, logs gains for second straight week

*

Euro zone January business activity grows -PMI

*

Sanofi falls on moderate profit growth forecast

Feb 3 (Reuters) - European shares rose on Friday, boosted by gains in healthcare and energy firms, as optimism over the outlook for the region's economy overshadowed concerns about U.S. interest rates staying elevated for longer than expected.

The pan-European STOXX 600 reversed early losses and ended up 0.3% at its highest since April last year. The index notched gains for the second straight week.

London's blue-chip FTSE 100 briefly hit a new record high on Friday, marking a potential turning point for UK assets. The index closed up 1%.

European equities rallied in the previous session on hopes that the global rate-hiking cycle was close to an end, even as the European Central Bank (ECB) stayed hawkish.

A report from the U.S. Labor Department on Friday showing

solid job additions in January

has weighed on such hopes, as a persistently tight labor market could allow the Federal Reserve to keep interest rates higher for longer.

However, analysts said the report also pointed to signs of resilience in the U.S. economy, which could alleviate some fears of a steep downturn.

In the euro zone,

business activity bounced back to growth in January, suggesting the bloc's economy might again escape a contraction this quarter and that the upturn might accelerate.

Another report showed euro zone producer prices

decelerated year-on-year

in December.

"You still have an economy holding up exceptionally well, particularly in the jobs market, and you have an earnings season that has not been so bad in Europe so far," said Giorgio Broggi, Quantitative Analyst at Moneyfarm.

"If inflation continues to stay under control in Europe and the U.S., then you expect a world where good news is good news, which means if the economy holds up, markets will do well."

Healthcare stocks led gains on the STOXX 600 on Friday, rising 1.5% on a boost from shares of large drugmakers such as Novo Nordisk and Roche Holding.

However, French drugmaker Sanofi fell 1.9% after forecasting moderate 2023 earnings growth.

Energy stocks jumped 1.0%, tracking crude prices higher as investors weighed demand recovery in top consumer China while some consumer staple stocks also lent a boost to the STOXX 600.

Dutch navigation and digital mapping company TomTom jumped 4.6% after raising its 2023 guidance.

Spain's Caixabank fell 2.7% as higher loan loss provisions overshadowed the Spanish bank's full-year results.

Casino fell 3.6% after analysts flagged that talks with Teract to combine French retail activities would not address the supermarket group's urgent need to slash debt. (Reporting by Ankika Biswas and Amruta Khandekar in Bengaluru; Editing by Savio D'Souza, Shinjini Ganguli and Mark Heinrich)

More News
12 Aug 2022 11:00

Drugmakers' shares stabilise after Zantac litigation slump

LONDON, Aug 12 (Reuters) - Shares in GSK, Sanofi , Haleon and Pfizer began to recover on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.

Read more
12 Aug 2022 09:01

GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump

LONDON, Aug 12 (Reuters) - Shares in GSK, Sanofi <SASY.PA and Haleon began to stabilise on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.

Read more
11 Aug 2022 22:15

GSK, Sanofi and Haleon shares slump on Zantac litigation concerns

LONDON, Aug 11 (Reuters) - Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing investor concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.

Read more
11 Aug 2022 18:45

GSK, Sanofi and Haleon shares slump on Zantac litigation concerns

LONDON, Aug 11 (Reuters) - Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing investor concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.

Read more
11 Aug 2022 17:29

European shares tick higher; Aegon shines on forecast raise

Aug 11 (Reuters) - European shares edged higher on Thursday after a strong rally in the previous session on signs of U.S. inflation cooling, while Aegon climbed after the Dutch insurer raised its full-year forecast.

Read more
11 Aug 2022 12:23

Haleon not a party to U.S. litigation focused on Zantac - spokesperson

LONDON, Aug 11 (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to the U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday.

Read more
10 Aug 2022 17:02

European bourses hold on to U.S. CPI boost

Aug 10 - Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com

EUROPEAN BOURSES HOLD ON TO U.S. CPI BOOST (1150 EDT/1550 GMT)

Read more
9 Aug 2022 16:59

European shares slip with U.S. inflation data in focus

Aug 9 (Reuters) - European shares dipped on Tuesday as investors cautiously waited for key U.S. inflation data later in the week for hints on the Federal Reserve's next move on interest rate increases.

Read more
28 Jul 2022 07:20

Sanofi lifts profit outlook as Dupixent sales surge 43%

July 28 (Reuters) - French healthcare group Sanofi lifted its full-year earnings outlook on continued forecast-beating sales growth for its bestselling drug Dupixent.

Read more
19 Jul 2022 13:00

As COVID patent war rages on, pharma group seeks fairer future access

LONDON, July 19 (Reuters) - An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights for COVID-19 interventions between the pharmaceutical industry and developing nations endures.

Read more
18 Jul 2022 12:19

GSK's consumer arm Haleon debuts with lacklustre valuation

LONDON, July 18 (Reuters) - British drugmaker GSK spun off its consumer health business on Monday in the biggest listing in Europe for more than a decade, but the unit's market value of 30.5 billion pounds fell well short of the price rival Unilever offered to pay earlier this year.

Read more
7 Jul 2022 15:25

EU drugs regulator open to COVID boosters that target older Omicron offshoots

LONDON, July 7 (Reuters) - The European Medicines Agency (EMA) is open to using next generation COVID-19 vaccines that target older offshoots of the Omicron variant this fall, an official said on Thursday, amid a rise in cases due to new Omicron subvariants.

Read more
24 Jun 2022 17:19

European shares mark strong end to nervous week

June 24 (Reuters) - European stocks jumped 2.6% on Friday, pushing them into positive territory for the week as investors started to scale back central bank tightening bets, spurring inflows into risky assets.

Read more
24 Jun 2022 17:08

Defensive stocks lead rebound in FTSE 100

June 24 (Reuters) - UK's FTSE 100 rose on Friday, lifted by defensive stocks at the end of a choppy week that saw investor anxiety over hawkish central banks, weak economic readings and heightened risks of a global recession.

Read more
24 Jun 2022 09:51

Sanofi, GSK variant-specific COVID shot found effective against Omicron

PARIS/LONDON, June 24 (Reuters) - Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.